Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

SAG

Copy Product Info
😃Good
Catalog No. T1779Cas No. 912545-86-9
Alias Smoothened Agonist

SAG (Smoothened Agonist) is a Smo receptor agonist (EC50=3 nM) that is cell-permeable and selective. SAG regulates Smo activity by binding directly to the Smo helix and can activate the Hedgehog signaling pathway.

SAG

SAG

Copy Product Info
😃Good
Purity: 98.88%
Catalog No. T1779Alias Smoothened AgonistCas No. 912545-86-9
SAG (Smoothened Agonist) is a Smo receptor agonist (EC50=3 nM) that is cell-permeable and selective. SAG regulates Smo activity by binding directly to the Smo helix and can activate the Hedgehog signaling pathway.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$41In StockIn Stock
2 mg$56In StockIn Stock
5 mg$83In StockIn Stock
10 mg$123In StockIn Stock
25 mg$246In StockIn Stock
50 mg$339In StockIn Stock
100 mg$503-In Stock
200 mg$718-In Stock
1 mL x 10 mM (in DMSO)$84In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.88%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
SAG (Smoothened Agonist) is a Smo receptor agonist (EC50=3 nM) that is cell-permeable and selective. SAG regulates Smo activity by binding directly to the Smo helix and can activate the Hedgehog signaling pathway.
Targets&IC50
HUVECs:22 μM, Shh Light II cells:8.8 nM (EC50), Smo:3 nM (EC50), C3H 10T1/2 cells:0.13 μM (EC50)
In vitro
METHODS: Embryonic stem cell ES were treated with SAG (0.5-1.25 µM) for 4-6 days and gene expression levels were measured using RT-qPCR.
RESULTS: Expression of Sim1, a post-mitotic V3 marker, was increased in all SAG-treated groups at all concentrations. The group treated with 0.5 μM SAG exhibited significantly higher levels of Nkx2.2 mRNA. Hb9 expression did not change significantly with SAG concentration at the given time points. [1]
METHODS: African green monkey kidney fibroblast-like cells, Cos-1, were treated with SAG (5-500 nM), and target protein expression levels were measured by Western Blot.
RESULTS: SAG inhibited cross-linking of ER-localized and post-ER forms of Smo-Myc3 to 125I-labeled PA cyclic amines in Cos-1 cells in a dose-dependent manner. cellular levels of Smo-Myc3 were not affected by agonist treatment. [2]
In vivo
METHODS: To explore whether the SHH signaling pathway plays a protective role in anxiety by regulating mitochondrial homeostasis, SAG (10 mg/kg) was intraperitoneally injected into C57BL/6 mice on a high-fat diet every three days for twelve weeks.
RESULTS: SHH signaling is neuroprotective in obesity, and SAG alleviates anxiety-like behaviors by reducing mitochondrial breaks. [3]
METHODS: To study the effects on developing limbs, SAG (15-20 mg/kg in lactated Ringer's solution) was administered as a single intraperitoneal injection to pregnant C57BL/6J mice at gestational day (GD) 9.25.
RESULTS: The most prevalent effect of SAG was the dose-dependent induction of preaxial polydactyly; defects ranged from thumb width to duplication of both digitiform fingers on the preaxial side of the thumb. [4]
Kinase Assay
In vitro Kinase Assays: Kinase assays for CDK1, CDK2 and GSK3-β are all carried out in a radiometric filter binding format. Assays for CDK5 are in DELFIA format and for CDKs 4 and 6 in ELISA format. For CDKs 1 and 2, the relevant CDK and 0.12 μg/mL Histone H1 are incubated in 20 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 0.1 mg/mL BSA, 45 μM ATP (0.78 Ci/mmol) and different concentrations of AT7519 for 2 or 4 hours respectively. For GSK3-β, the relevant enzyme and 5 μM glycogen synthase peptide 2 along with 10 mM MOPS pH 7.0, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% glycerol, 0.2 mM EDTA, 10 mM MgCl2, 0.01% β-mercaptoethanol, 15 μM ATP (2.31 Ci/mmol) and different concentrations of AT7519 are incubated for 3 hours. Assay reactions are stopped by adding an excess of orthophosphoric acid and filtered using Millipore MAPH filter plates. The plates are then washed, scintillant added and radioactivity measured by scintillation counting on a Packard TopCount. For CDK5, CDK5/p35 and 1 μM of a biotinylated Histone H1 peptide (Biotin-PKTPKKAKKL) are incubated in 25 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 0.025% Brij-35, 0.1 mg/mL BSA, 1 mM DTT, 15 μM ATP and different concentrations of AT7519 for 30 minutes. Assay reactions are stopped using EDTA, transferred to Neutravidin-coated plates and phosphorylated peptide quantified by means of a rabbit phospho-cdk1 substrate polyclonal antibody and DELFIA europium-labelled anti-rabbit IgG secondary antibody using time-resolved fluorescence at λex=335 nM, λem=620 nM. For CDK 4 and 6 assays, plates are coated with GST- pRb769-921 and blocked with Superblock. CDK4 or 6 is incubated with 15 mM MgCl2, 50 mM HEPES, pH 7.4, 1 mM DTT, 1 mM EGTA, pH 8.0, 0.02% Triton X-100, 2.5% DMSO and different concentrations of AT7519; the reaction is initiated by addition of ATP. After 30 minutes, reactions are stopped by the addition of 0.5 M EDTA pH 8.0.Plates are then washed and incubated for one hour with the primary antibody (anti- p-Rb Serine 780) diluted in Superblock followed by secondary antibody (alkaline phosphatase linked anti-rabbit) for a further hour. Plates are developed using the Attophos system and fluorescence read on a Spectramax Gemini plate reader at excitation 450 nm and emission 580 nm. In all cases, IC50 values are calculated from replicate curves, using GraphPad Prism software.
SynonymsSmoothened Agonist
Chemical Properties
Molecular Weight490.06
FormulaC28H28ClN3OS
Cas No.912545-86-9
SmilesCN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl
Relative Density.1.30 g/cm3 (Predicted)
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 252.5 mg/mL (515.24 mM), Heating is recommended.
Ethanol: 40 mg/mL (81.62 mM), Heating is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.5 mg/mL (11.22 mM), Solution.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.0406 mL10.2028 mL20.4057 mL102.0283 mL
5 mM0.4081 mL2.0406 mL4.0811 mL20.4057 mL
10 mM0.2041 mL1.0203 mL2.0406 mL10.2028 mL
20 mM0.1020 mL0.5101 mL1.0203 mL5.1014 mL
50 mM0.0408 mL0.2041 mL0.4081 mL2.0406 mL
DMSO
1mg5mg10mg50mg
100 mM0.0204 mL0.1020 mL0.2041 mL1.0203 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy SAG | purchase SAG | SAG cost | order SAG | SAG chemical structure | SAG in vivo | SAG in vitro | SAG formula | SAG molecular weight